// App-Quantinova.ai

3008 : Preclinical characterization of AMG 900, a pan-aurora kinase inhibitor, alone and in combination with taxanes in ovarian cancer

Researchers

Presenter

  • Ondrej Kalous

Principal Investigators

  • Dylan Conklin

  • Kanthinh Manivong

  • William Wayne

  • Kelly Hanestad

  • Jude Canon

  • Robert Loberg

  • Gregory Friberg

  • Erick Gamelin

  • Florian D. Vogl

  • Gloria Juan

  • Angela Coxon

  • Dennis Slamon

  • Richard Finn

  • Marc Payton

Medical Centers

  • UCLA, Division of Hematology and Oncology, Department of Medicine, Jonsson Comprehensive Cancer Center, Santa Monica, CA

  • Amgen Inc, Thousand Oaks, CA

Locations

  • United States

Companies

  • Amgen Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Gynaecological cancer

  • Solid malignancies

Biomarkers

  • Aurora kinase A

  • p53

  • cMYC

  • Tumor protein p53

Drug/Treatment

  • Carboplatin

  • Doxorubicin

  • Paclitaxel

  • Docetaxel

  • AMG-900

  • taxane

  • TP53

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved